White blood cells and chronic rhinosinusitis: a Mendelian randomization study.

"Declarations Ethics approval and consent to participateUK Biobank received ethical approval from the Research Ethics Committee (REC reference for UK Biobank is 11/NW/0382). The INTERVAL study was approved by the Cambridge (East) Research Ethics Committee. Informed consent was obtained from all participants of the UK Biobank, UK BiLEVE, and INTERVAL studies. Patients and control subjects in FinnGen provided informed consent for biobank research, based on the Finnish Biobank Act. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) approved the FinnGen study protocol Nr HUS/990/2017. The FinnGen study is approved by Finnish Institute for Health and Welfare (THL), approval. number THL/2031/6.02.00/2017, amendments THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019, Digital and population data service agency VRK43431/2017–3, VRK/6909/2018–3, VRK/4415/2019–3 the Social Insurance Institution (KELA) KELA 58/522/2017, KELA 131/522/2018, KELA. 70/522/2019, KELA 98/522/2019, and Statistics Finland TK-53–1041-17. Consent for publicationNot applicable. Competing interestsThe authors declare that they have no competing interests. Competing interests The authors declare that they have no competing interests."

"Funding This work was supported by grants from the National Heart, Lung and Blood Institute (R01 HL136659). The funding sources played no role in the design, conduct, or reporting of this study. The content of this article is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health (NIH) or the Mayo Clinic."